Login to Your Account



Algeta's Manufacturing Hiccup Delays Alpharadin Applications

By Nuala Moran
Staff Writer

Wednesday, August 22, 2012

LONDON – A hitch at Algeta ASA's new facility for manufacturing commercial supplies of Alpharadin has pushed back the filing date for the alpha radiation treatment for bone metastases from midyear to the end of 2012.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription